by mpzzqmvj | Mar 4, 2021 | Press Releases
Topline results from Phase 1/2 study on track for March 2021Individual and cumulative data seen to-date show Trappsol® Cyclo™ to be well tolerated with a favorable safety profile for all dose groups and to have encouraging signals in efficacyPivotal Phase 3...
by mpzzqmvj | Mar 1, 2021 | Press Releases
– Seasoned biotechnology executive with 20-year successful track record of drug development for rare genetic diseases and extensive worldwide regulatory experience – Internationally renowned for clinical development of innovative drugs with broad...
by mpzzqmvj | Feb 22, 2021 | Press Releases
– The evolution of the Company’s brand identity aligns with Cyclo Therapeutics’ science-based, patient-focus approach to drug development- Company developing cyclodextrin-based products for the treatment of diseases with significant unmet needs,...
by mpzzqmvj | Feb 9, 2021 | Press Releases
Data from ongoing Phase 1 extension study shows improvement in disease features or disease stabilization with home-based intravenous infusions of Trappsol® Cyclo™Phase 1 biomarker 24S-hydroxycholesterol demonstrates clearance of excess cholesterol from the...
by mpzzqmvj | Jan 26, 2021 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including...
by mpzzqmvj | Jan 5, 2021 | Press Releases
Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilizationGAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company...
